Shots: The companies reported the selection of DC for VIR-2703 (ALN-COV) targeting SARS-CoV-2 genome and intend to meet US FDA & other regulatory authorities for IND filing with a plan to commence human studies by the end of 2020 In Oct, 2017, Alnylam and Vir entered into an exclusive license agreement to develop and commercialize […]Read More
